Comparative Pharmacology
Head-to-head clinical analysis: PLETAL versus TICLID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLETAL versus TICLID.
PLETAL vs TICLID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cilostazol inhibits phosphodiesterase III (PDE3), increasing cAMP levels in platelets and vascular smooth muscle, leading to platelet inhibition and vasodilation.
Ticlopidine is a thienopyridine ADP receptor antagonist that irreversibly inhibits the P2Y12 receptor on platelets, preventing ADP-induced platelet aggregation.
100 mg orally twice daily, administered at least 30 minutes before or 2 hours after meals.
250 mg orally twice daily
None Documented
None Documented
Terminal half-life of cilostazol is approximately 11-13 hours; for active metabolites 3,4-dehydro-cilostazol (about 4-6 times more active) half-life is similar. Steady state achieved within a few days.
Terminal elimination half-life is approximately 30-50 hours (mean ~33 hours), with clinical effects lasting 7-10 days after discontinuation due to irreversible platelet binding.
Renal (approximately 77% as metabolites, <1% unchanged); fecal (approximately 18%)
Primarily hepatic metabolism; 60% renal as metabolites, 23% fecal. Minimal parent drug excreted unchanged.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent